Comparison between capecitabine plus oxaliplatin and 5-fluorouracil/ leucovorin( 5-FU/LV) plus oxaliplatin in treatment of 95 patients with advanced colorectal cancer
YANG Lan,DENG Ying,HU Honglin,and PAN Haixia
YANG Lan, DENG Ying, HU Honglin, and PAN Haixia. Department of Oncology, People’s Hospital of Sichuan Province, Chengdu 610072, China
Abstract：Objective To compare the efficacy and untoward reactions of capecitabine plus oxaliplatin (XELOX) regimen and oxaliplatin plus 5 - fluorouracil/leucovorin (5-FU/LV) (FOLFOX4) in the treatment of advanced colorectal cancer. Methods Totally 95 patients with metastatic and recurring colorectal cancer were enrolled into this study. Patients were randomly divided into XELOX (n=47) and FOLFOX4 (n=48) groups. Patients in XELOX group were treated with capecitabine 1 000 mg/m2, p o, bid, for 14 days, and oxaliplatin 130 mg/m2, ivgtt on d 1. Patients in FOLFOX4 group were treated with oxaliplatin 85 mg/m2, ivgtt on d 1; LV 200 mg/m2 ivgtt for 2 h followed by 5-FU 400 mg/m2 (bolus) and 5-FU 600 mg/m2 (22 h-coutinous in fusion), on d 1, 2. XELOX regimen was repeated every 3 weeks for one cycle; FOLFOX4 regimen was repeated every 2 weeks, and 4 weeks for one cycle. All patients received two cycles of chemotherapy or more. The toxicity was evaluated according to RECIST criteria, Karnofsky scores and NCICTC 3.O version criteria. Results All the 95 patients were available for evaluating objective response.In XELOX group, the overall response rate was 48. 9% (CR:4, PR:19), the disease control rate was 85.1%.In FOLFOX4 group, the overall response rate was 50.0% (CR:4, PR:20), the disease control rate was 89.5%; the toxicities were well tolerated.In XELOX group, the major side effects were gastrointestinal tract reactions, hematologic toxicity, stomatitis, alopecia; their incidence rates were significantly lower than those in FOLFOX4 group (P<0.05). The peripheral nerve toxicity and thrombocytopenia incidence rates were not significantly different between the two group. The incidence rate of hand-foot syndrome was higher in XELOX group than in FOLFOX4 group (P<0.05), but the severity was less (grade Ⅰ～Ⅱ). Conclusions The response rate is not markedly different between the two regimens.XELOX regimen is safer and its use is more convenient than FOLFOX4 regimen. Therefore, XELOX regimen is worth recommending as a first line therapy for the treatment of advanced colorectal cancer patients.
杨 兰,邓 颖,胡洪林,潘海霞. XELOX方案与FOLFOX4方案治疗晚期结直肠癌疗效比较[J]. , 2014, 25(3): 221-223.
YANG Lan,DENG Ying,HU Honglin,and PAN Haixia. Comparison between capecitabine plus oxaliplatin and 5-fluorouracil/ leucovorin( 5-FU/LV) plus oxaliplatin in treatment of 95 patients with advanced colorectal cancer. , 2014, 25(3): 221-223.
Schmoll H J, Tabernero J, Maroun J A, et al. Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage Ⅲ colon cancer: survival follow-up of study NO16968 (XELOXA)[J]. ASCO Meeting Abstracts, 2012, 30(4):388.
[2]
Schmoll H J, Tabernero J, Maroun J A, et al. Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage Ⅲ colon cancer: survival follow-up of study NO16968 (XELOXA)[J]. ASCO Meeting Abstracts, 2012, 30(4):388.
[3]
Ducreux M, Bennouna J, Hebbar M, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer[J]. Int J Cancer, 2011, 128:682-690.
[3]
Ducreux M, Bennouna J, Hebbar M, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer[J]. Int J Cancer, 2011, 128:682-690.
2014, Vol. 25 
